NASDAQ:ZGNX - Zogenix Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$48.60 +0.55 (+1.14 %)
(As of 08/20/2018 01:05 AM ET)
Previous Close$48.60
Today's Range$47.10 - $49.05
52-Week Range$11.40 - $62.75
Volume1.23 million shs
Average Volume643,211 shs
Market Capitalization$1.80 billion
P/E Ratio-12.09
Dividend YieldN/A
Beta2.13
Zogenix logoZogenix, Inc., a pharmaceutical company, develops and commercializes therapies for the treatment of central nervous system disorders in the United States. Its lead product candidate is the ZX008, a low-dose fenfluramine, which is in Phase III clinical trials for the treatment of seizures associated with Dravet syndrome. The company was formerly known as SJ2 Therapeutics, Inc. and changed its name to Zogenix, Inc. in August 2006. Zogenix, Inc. was founded in 2006 and is headquartered in Emeryville, California.

Receive ZGNX News and Ratings via Email

Sign-up to receive the latest news and ratings for ZGNX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
SymbolNASDAQ:ZGNX
CUSIP98978L10
Phone510-550-8300

Debt

Debt-to-Equity RatioN/A
Current Ratio6.89
Quick Ratio6.89

Price-To-Earnings

Trailing P/E Ratio-12.09
Forward P/E Ratio-13.06
P/E GrowthN/A

Sales & Book Value

Annual Sales$9.82 million
Price / Sales177.33
Cash FlowN/A
Price / CashN/A
Book Value$8.80 per share
Price / Book5.52

Profitability

EPS (Most Recent Fiscal Year)($4.02)
Net Income$-126,810,000.00
Net MarginsN/A
Return on Equity-55.07%
Return on Assets-36.30%

Miscellaneous

Employees68
Outstanding Shares35,830,000
Market Cap$1.80 billion

Zogenix (NASDAQ:ZGNX) Frequently Asked Questions

What is Zogenix's stock symbol?

Zogenix trades on the NASDAQ under the ticker symbol "ZGNX."

How were Zogenix's earnings last quarter?

Zogenix, Inc. (NASDAQ:ZGNX) announced its quarterly earnings results on Monday, August, 6th. The company reported ($0.82) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.88) by $0.06. During the same quarter last year, the business earned ($0.90) EPS. View Zogenix's Earnings History.

When is Zogenix's next earnings date?

Zogenix is scheduled to release their next quarterly earnings announcement on Tuesday, November, 6th 2018. View Earnings Estimates for Zogenix.

What price target have analysts set for ZGNX?

6 Wall Street analysts have issued twelve-month price objectives for Zogenix's shares. Their predictions range from $54.00 to $69.00. On average, they anticipate Zogenix's stock price to reach $62.80 in the next twelve months. This suggests a possible upside of 29.2% from the stock's current price. View Analyst Price Targets for Zogenix.

What is the consensus analysts' recommendation for Zogenix?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Zogenix in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Zogenix.

What are Wall Street analysts saying about Zogenix stock?

Here are some recent quotes from research analysts about Zogenix stock:
  • 1. Mizuho analysts commented, "We do not see earnings as the most meaningful indicator of value for a development-stage biotech. Importantly, Zogenix remains on track to file regulatory applications in the U.S. and by year-end 2018. With a recent $359 mil equity offering, we think Zogenix is now in a position to comfortably reach break-even without the need for additional capital." (8/9/2018)
  • 2. According to Zacks Investment Research, "Zogenix, Inc. is a pharmaceutical company engaged in the development and commercialization of treatment products for central nervous system disorders and pain. Its first commercial product, Sumavel™ DosePro™ is a needle-free Delivery System used in the treatment of acute migraine and cluster headache in a pre-filled, single-use delivery system. Its lead product candidate, ZX002, is a novel, oral and single-entity controlled-release formulation of hydrocodone used for the treatment of moderate to severe chronic pain in patients requiring around-the-clock opioid therapy. Zogenix, Inc. is headquartered in San Diego, CA. " (6/21/2018)

Who are some of Zogenix's key competitors?

Who are Zogenix's key executives?

Zogenix's management team includes the folowing people:
  • Dr. Stephen J. Farr, Co-Founder, CEO, Pres & Director (Age 59)
  • Mr. Roger L. Hawley B.S., Co-Founder & Director (Age 65)
  • Mr. Michael P. Smith, Exec. VP, CFO, Treasurer & Sec. (Age 50)
  • Dr. Bradley S. Galer, Exec. VP & Chief Medical Officer (Age 56)
  • Dr. Gail M. Farfel, Exec. VP & Chief Devel. Officer (Age 54)

Has Zogenix been receiving favorable news coverage?

News coverage about ZGNX stock has been trending somewhat positive on Monday, Accern reports. Accern identifies negative and positive news coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Zogenix earned a coverage optimism score of 0.12 on Accern's scale. They also assigned news articles about the company an impact score of 44.70 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company's share price in the next few days. View Recent Headlines for Zogenix.

Who are Zogenix's major shareholders?

Zogenix's stock is owned by many different of institutional and retail investors. Top institutional investors include Scopia Capital Management LP (9.79%), BlackRock Inc. (8.20%), Cadian Capital Management LP (5.73%), Bank of New York Mellon Corp (4.36%), FMR LLC (3.57%) and Federated Investors Inc. PA (3.29%). Company insiders that own Zogenix stock include Bradley S Galer, Cam L Garner, Gail M Farfel, Life Sciences Maste Perceptive, Renee P Tannenbaum and Roger Hawley. View Institutional Ownership Trends for Zogenix.

Which major investors are selling Zogenix stock?

ZGNX stock was sold by a variety of institutional investors in the last quarter, including Rhenman & Partners Asset Management AB, Federated Investors Inc. PA, FMR LLC, Dimensional Fund Advisors LP, Cadian Capital Management LP, Point72 Asset Management L.P., Eagle Asset Management Inc. and Cheyne Capital Management UK LLP. Company insiders that have sold Zogenix company stock in the last year include Cam L Garner, Gail M Farfel and Roger Hawley. View Insider Buying and Selling for Zogenix.

Which major investors are buying Zogenix stock?

ZGNX stock was bought by a variety of institutional investors in the last quarter, including Bank of New York Mellon Corp, BlackRock Inc., Tavio Capital LLC, Scopia Capital Management LP, Chartwell Investment Partners LLC, First Trust Advisors LP, Sei Investments Co. and Schwab Charles Investment Management Inc.. Company insiders that have bought Zogenix stock in the last two years include Bradley S Galer, Life Sciences Maste Perceptive and Renee P Tannenbaum. View Insider Buying and Selling for Zogenix.

How do I buy shares of Zogenix?

Shares of ZGNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Zogenix's stock price today?

One share of ZGNX stock can currently be purchased for approximately $48.60.

How big of a company is Zogenix?

Zogenix has a market capitalization of $1.80 billion and generates $9.82 million in revenue each year. The company earns $-126,810,000.00 in net income (profit) each year or ($4.02) on an earnings per share basis. Zogenix employs 68 workers across the globe.

How can I contact Zogenix?

Zogenix's mailing address is 5858 Horton Street Suite 455, EMERYVILLE CA, 94608. The company can be reached via phone at 510-550-8300 or via email at [email protected]


MarketBeat Community Rating for Zogenix (NASDAQ ZGNX)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  302 (Vote Outperform)
Underperform Votes:  203 (Vote Underperform)
Total Votes:  505
MarketBeat's community ratings are surveys of what our community members think about Zogenix and other stocks. Vote "Outperform" if you believe ZGNX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ZGNX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 8/20/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel